Gazyva (obinutuzumab) / Roche, Biogen 
Welcome,         Profile    Billing    Logout  
 23 Diseases   163 Trials   163 Trials   4765 News 


«12...3637383940414243444546...6061»
  • ||||||||||  Gazyva (obinutuzumab) / Biogen, Roche
    Evidence for serial antibody-dependent cell-mediated cytotoxicity (ADCC) by primary unstimulated human natural killer (NK) lymphocytes  (Board Number: P484) -  Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_279;    
    Human ADCC measured by 51Cr-release at multiple NK effector to tumor cell ratios (E:Ts) was largely finished after 4 hours when the targets were Daudi B leukemia cells coated with non-fucosylated obinutuzumab anti-CD20...We conclude that this gross measurement (D/E) can detect serial ADCC even without the information provided by time-lapse cinematography to indicate the actual fraction of effectors that are serial killers. This simple measurement may be useful to screen for promotion of serial killing by reagents that reduce proteolytic loss of NK cell CD16A.
  • ||||||||||  Brukinsa (zanubrutinib) / BeiGene
    Trial completion date, Trial primary completion date, Combination therapy:  BGB-3111_GA101_Study_001: BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies (clinicaltrials.gov) -  Apr 24, 2020   
    P1b,  N=119, Active, not recruiting, 
    This simple measurement may be useful to screen for promotion of serial killing by reagents that reduce proteolytic loss of NK cell CD16A. Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal:  The evolving treatment landscape of chronic lymphocytic leukemia. (Pubmed Central) -  Apr 23, 2020   
    A deep knowledge of currently available evidences is key to tailor treatment choice and optimize long-term tolerability and disease control. Fixed-duration combinations are investigated to allow treatment holidays and avoid the emergence of resistant clones under the selective pressure of continuous treatment.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Retrospective data, Journal:  A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia. (Pubmed Central) -  Apr 9, 2020   
    All maintenance therapies were effective in reducing the risk of disease progression versus no intervention. Based on current best evidence, maintenance therapy with lenalidomide is the most efficacious option.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Review, Journal:  Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. (Pubmed Central) -  Apr 4, 2020   
    Despite more than 5 million worldwide exposures to date (and about 500 000 new exposures per year), insufficient data collection has hampered identification of risk minimization strategies, and concerns have been raised about a class effect extending to the newer anti-CD20 monoclonal antibodies (ofatumumab, obinutuzumab, and ocrelizumab). Here, we report current PML case counts registered in the FAERS and EudraVigilance databases and comment on severe CD4 T lymphopenia as a plausible common mechanism of action for anti-CD20 antibodies in causation of PML.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
    USING NOVEL AGENTS TO TREAT A RARE CASE OF CLL/SLL IN AN ADOLESCENT PATIENT () -  Apr 3, 2020 - Abstract #ASPHO2020ASPHO_400;    
    The treatment duration of 12 months and low side effect profile made this combination an ideal treatment option for our adolescent patient. To our knowledge, this is the first reported case of CLL/SLL in an adolescent patient treated with novel therapeutic agents.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, ibrutinib / Generic mfg.
    Clinical, Review, Journal:  Pharmacists' Role in Managing Patients with Chronic Lymphocytic Leukemia. (Pubmed Central) -  Apr 2, 2020   
    Furthermore, additional credentialing of clinical pharmacists in select states allows for independent visits with the pharmacists, allowing for greater involvement, particularly for initiation of venetoclax and management of ibrutinib-induced toxicities. Pharmacists are essential to both expanding and enhancing the care of patients with CLL and should be leveraged to improve patient outcomes whenever possible.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Review, Journal:  BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. (Pubmed Central) -  Apr 2, 2020   
    One ongoing question is whether the addition of anti-CD20 monoclonal antibodies improve response or response durability with BTK inhibitors. In this review, we will discuss clinical trials of ibrutinib and acalabrutinib in older patients with CLL, and the possible contributions of anti-CD20 antibodies to these therapies.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  VENOBI-CNS: Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (clinicaltrials.gov) -  Apr 2, 2020   
    P1,  N=15, Recruiting, 
    In this review, we will discuss clinical trials of ibrutinib and acalabrutinib in older patients with CLL, and the possible contributions of anti-CD20 antibodies to these therapies. Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Mar 2024 | Initiation date: Nov 2019 --> Apr 2020 | Trial primary completion date: Apr 2023 --> Jul 2023
  • ||||||||||  Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Review, Journal:  Clinical application of obinutuzumab for treating chronic lymphocytic leukemia. (Pubmed Central) -  Mar 31, 2020   
    In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. This review summarizes the results of clinical studies using obinutuzumab and looks forward to its further application in treating CLL clinically.
  • ||||||||||  Quzyttir (cetirizine injection) / TerSera Therap
    Enrollment open:  TER-QZTR-001: Phase 2 Study IV QUZYTTIR (clinicaltrials.gov) -  Mar 30, 2020   
    P2,  N=34, Recruiting, 
    This review summarizes the results of clinical studies using obinutuzumab and looks forward to its further application in treating CLL clinically. Not yet recruiting --> Recruiting
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal, IO Biomarker:  Chronic lymphocytic leukemia: 2019 update on diagnosis, risk stratification and treatment. (Pubmed Central) -  Mar 29, 2020   
    Deletions of the short arm of chromosome 17 (del(17p)) and/or mutations of the TP53 gene predict resistance to chemoimmunotherapy and a shorter time to progression with most targeted therapies. A comprehensive, international prognostic score (CLL-IPI) integrates genetic, biological and clinical variables to identify distinct risk groups of CLL patients.
  • ||||||||||  Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal:  The role of obinutuzumab in the management of follicular lymphoma. (Pubmed Central) -  Mar 26, 2020   
    Obinutuzumab (a first-in-class, glycoengineered, humanized type 2 anti-CD20 antibody) has been evaluated in a number of clinical trials. In this review, we will summarize the evaluable results of clinical trials investigating the efficacy of obinutuzumab in the treatment of FL.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
    Enrollment closed, Trial completion date, Trial primary completion date:  OAsIs: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (clinicaltrials.gov) -  Mar 13, 2020   
    P1/2,  N=48, Active, not recruiting, 
    Trial primary completion date: Mar 2020 --> Mar 2021 Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Apr 2018 --> Apr 2019
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
    Trial primary completion date:  LYSA: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (clinicaltrials.gov) -  Mar 13, 2020   
    P2,  N=138, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Apr 2018 --> Apr 2019 Trial primary completion date: Jan 2020 --> Sep 2019
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal:  Current targeted therapies in lymphomas. (Pubmed Central) -  Mar 12, 2020   
    Further opportunities are warranted to identify patients who are most likely to achieve durable response and reduce the risk of disease progression. Ongoing trials with current and investigational agents may further elucidate their place in therapy and therapeutic benefits.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Biogen, Roche
    Journal:  Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia. (Pubmed Central) -  Mar 3, 2020   
    With the expanding number of therapeutic alternatives available for CLL, discussion of efficacy and potential adverse effects are paramount to formulating the optimal treatment regimen for each individual patient. Many ongoing studies will further define the ideal combination and long-term efficacy of these novel therapies in a prospective manner.
  • ||||||||||  FT596 / Fate Therap
    Enrollment open, Combination therapy, Monotherapy:  FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies (clinicaltrials.gov) -  Mar 3, 2020   
    P1,  N=123, Recruiting, 
    Many ongoing studies will further define the ideal combination and long-term efficacy of these novel therapies in a prospective manner. Not yet recruiting --> Recruiting